ClinicalTrials.gg
Not yet recruitingNCT07833553Updated Oct 16, 2026

Comparison of Efficacy of Caudal Versus Transforaminal Epidural Steroid Injections in Unilateral S1 Nerve Root Pain: A Randomized Controlled Trial

An interventional study of Caudal Epidural Steroid Injection (CEI) and Transforaminal Epidural Steroid Injection (TFI) in Unilateral S1 Nerve Root Pain, sponsored by University of Health Sciences Lahore. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study compares caudal and transforaminal epidural steroid injections for treating unilateral S1 nerve root pain. It evaluates pain relief, functional improvement, treatment satisfaction, quality of life, and complications over 12 months.

Read the detailed description

Unilateral S1 nerve root pain is a common manifestation of lumbosacral radiculopathy and may persist despite conservative treatment. Epidural steroid injections are used as an interventional treatment option for patients with persistent radicular pain. Different approaches to epidural steroid delivery may produce different patterns of pain relief and functional improvement, but their comparative clinical effectiveness in patients with unilateral S1 nerve root pain remains an important clinical question.

This randomized controlled trial was designed to compare two approaches to epidural steroid administration: caudal epidural steroid injection and transforaminal epidural steroid injection. The study focuses on patients with unilateral S1 nerve root pain associated with imaging-confirmed nerve root compression who have persistent symptoms despite conservative management.

The principal purpose of the study is to characterize and compare the clinical response associated with the two injection approaches over an extended follow-up period. The study evaluates changes in pain and functional status together with patient-reported quality of life and satisfaction with treatment. The study also considers the duration and sustainability of treatment effects and documents treatment-related complications and adverse events.

The comparison is intended to provide clinical information regarding the relative effectiveness and safety of the two epidural injection approaches in the management of unilateral S1 nerve root pain. Assessment across multiple follow-up points allows the study to examine both the early response following treatment and the persistence of clinical effects over time.

The study uses a parallel-group randomized controlled design in which eligible participants are allocated to receive either caudal or transforaminal epidural steroid injection. The study procedures, eligibility criteria, outcome measures, follow-up schedule, and statistical methods are described in their respective sections of the clinical trial record.

02

Conditions studied

  • Unilateral S1 Nerve Root Pain

Browse trials for

Keywords

  • Radiculopathy
  • Epidural Steroid Injections
  • Lumbar radicular pain
  • S1 Radiculopathy
  • Oswestry Disability Index
  • Glucocorticoids
03

In context

Radiculopathy

483 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 373 interventional studies indexed under Radiculopathy.

Browse Radiculopathy studies →

Lead sponsor

University of Health Sciences Lahore is the lead sponsor of 83 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years.
  • Clinical symptoms and MRI confirmation of unilateral S1 nerve root compression.
  • Pain duration > 6 weeks despite conservative therapy.

Exclusion criteria

Exclusion Criteria:

  • Previous epidural injection in the past 6 months.
  • Significant neurological deficits requiring immediate surgery.
  • Coagulopathy or current anticoagulant therapy.
  • Allergy to corticosteroids or contrast agents.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Group A: Caudal Epidural Steroid Injection (CEI)

    Participants receive a caudal epidural steroid injection through the sacral hiatus under fluoroscopic guidance. A corticosteroid combined with a local anesthetic is administered into the epidural space, with contrast dye used to confirm proper needle placement and epidural distribution.

    Procedure: Caudal Epidural Steroid Injection (CEI)

  • Active comparator
    Group B: Transforaminal Epidural Steroid Injection (TFI)

    Participants receive a transforaminal epidural steroid injection targeting the affected S1 neural foramen under fluoroscopic guidance. A corticosteroid and local anesthetic mixture is administered, with contrast dye used to confirm proper epidural distribution.

    Procedure: Transforaminal Epidural Steroid Injection (TFI)

Interventions

  • ProcedureCaudal Epidural Steroid Injection (CEI)

    A caudal epidural steroid injection is administered through the sacral hiatus into the epidural space under fluoroscopic guidance. Corticosteroid combined with a local anesthetic is administered, and contrast dye is used to confirm proper needle placement.

  • ProcedureTransforaminal Epidural Steroid Injection (TFI)

    A transforaminal epidural steroid injection is administered into the affected S1 neural foramen under fluoroscopic guidance. A steroid and local anesthetic mixture is administered, with contrast dye used to confirm proper epidural distribution.

06

What researchers measure

Primary outcomes

  1. Pain intensity measured by Visual Analogue Scale (VAS)

    Pain intensity will be assessed using the Visual Analogue Scale (VAS) to compare pain relief between caudal epidural steroid injection and transforaminal epidural steroid injection groups.

    Time frame: Baseline, 1 week, 1 month, 3 months, 6 months, and 12 months after intervention

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    Functional disability will be assessed using the Oswestry Disability Index (ODI) to compare functional outcomes between the caudal epidural steroid injection and transforaminal epidural steroid injection groups.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months after intervention

  2. Health-Related Quality of Life measured by SF-36

    Health-related quality of life will be assessed using the Short Form-36 (SF-36) questionnaire to compare quality-of-life outcomes between the two treatment groups.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months after intervention

  3. Duration of Pain Relief

    The duration and sustainability of pain relief following epidural steroid injection will be assessed and compared between the two treatment groups.

    Time frame: From 1 week through 12 months after intervention

  4. Procedure-Related Complications

    Procedure-related complications will be recorded and compared between participants receiving caudal and transforaminal epidural steroid injections.

    Time frame: From intervention through 12 months after intervention

  5. Change in Functional Outcome Over 12 Months

    Changes in functional status over the follow-up period will be assessed using the Oswestry Disability Index (ODI) and compared between the two treatment groups.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months after intervention

07

Study locations

1 site
08

References and documents

Publications

  • Song JH, Lee WY, Cho KR, Nam SH, Park KD, Park Y. Fluoroscopy-Guided Transforaminal versus Caudal Epidural Steroid Injection for Chronic Pain After Spinal Surgery: A Retrospective Mid-Term Comparative Study. J Pain Res. 2021 Jul 13;14:2129-2138. doi: 10.2147/JPR.S314044. eCollection 2021. PubMed 34285573 ↗
  • Li T, Gonzalez C, Provost J, Hasoon J, Nguyen A. Understanding the Landscape of Lumbar Epidural Steroid Injections: A Review of Interlaminar, Transforaminal, and Caudal Approaches. Orthop Rev (Pavia). 2025 May 23;17:138210. doi: 10.52965/001c.138210. eCollection 2025. PubMed 40416592 ↗
  • Lee E, Lee JW, Kang HS. Interlaminar versus transforaminal epidural steroid injections: a review of efficacy and safety. Skeletal Radiol. 2023 Oct;52(10):1825-1840. doi: 10.1007/s00256-022-04124-3. Epub 2022 Jul 20. PubMed 35859019 ↗
  • Imani F, Mohammad-Esmaeel F, Morsalli SF, Ahani-Azari A, Alimian M, Nikoubakht N, Emami A. Comparison of Clinical Effects and Physical Examination of Transforaminal and Caudal Steroid Injection With Targeted Catheter in Lumbar Radiculopathy: A Single-Blind Randomized Clinical Trial. Brain Behav. 2024 Oct;14(10):e70067. doi: 10.1002/brb3.70067. PubMed 39363795 ↗
  • Ozturk EC, Sacaklidir R, Sencan S, Gunduz OH. Caudal epidural steroid injection versus transforaminal ESI for unilateral S1 radiculopathy: a prospective, randomized trial. Pain Med. 2023 Aug 1;24(8):957-962. doi: 10.1093/pm/pnad041. PubMed 37004169 ↗
  • Choi EJ, Park SJ, Yoo YM, Yoon JU, Shin SW, Byeon GJ. Comparison of the Oblique Interlaminar and Transforaminal Lumbar Epidural Steroid Injections for Treatment of Low Back and Lumbosacral Radicular Pain. J Pain Res. 2021 Feb 15;14:407-414. doi: 10.2147/JPR.S293166. eCollection 2021. PubMed 33623423 ↗
  • Bensler S, Walde M, Fischer MA, Pfirrmann CW, Peterson CK, Sutter R. Comparison of treatment outcomes in lumbar disc herniation patients treated with epidural steroid injections: interlaminar versus transforaminal approach. Acta Radiol. 2020 Mar;61(3):361-369. doi: 10.1177/0284185119858681. Epub 2019 Jul 2. No abstract available. PubMed 31265320 ↗
  • Ahmed M, Ahmad A, Arshad M, Naseer H, Zamarud A. Ultrasound-Guided Versus Conventional Fluoroscopy-Guided Epidural Injection for Radiculopathy. A Meta-Analysis of Randomized Controlled Trials. World Neurosurg. 2023 Dec;180:203-212.e4. doi: 10.1016/j.wneu.2023.09.088. Epub 2023 Sep 27. PubMed 37774791 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2028, 12 months later.

Of 203 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 12 months is close to that.

Counting every sponsor, half of 215 studies reached it within 12 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartEst.
Jan 5, 2027
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 5, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and responsible party
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07833553
Lead sponsor
University of Health Sciences Lahore
Responsible party
Ahmad (Speciality Registrar, University of Health Sciences Lahore) — Principal investigator
First posted
Sep 22, 2026
Start date
Jan 5, 2027 (estimated)
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 5, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Dr. Kashif Hussain
Contact
Kashifhussain543@hotmail.com
+923334841745
Prof Dr. Leena Aziz
Contact
leenayub@gmail.com
Dr. Kashif Hussain
study chair · Ghurki Trust & Teaching Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion